E7F0 Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EDT
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.19M
Enterprise Value€12.21M
Total Cash (Recent Filing)€116.00K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding424,963,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-18.07
Price to Sales (P/S)0.00
P/FCF Ratio-12.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Early‑detection DiagnosticsA concentrated business model targeting blood‑based early lung cancer detection aligns with durable structural demand for earlier, less invasive diagnostics. Specialization can build domain expertise and regulatory/clinical relationships that support long‑term clinical adoption and commercialization pathways.
Very Low Reported LeverageMinimal reported debt reduces fixed financing obligations and bankruptcy risk, giving management flexible capital structure options. For a pre‑revenue biotech, low leverage preserves capacity to raise equity or partner strategically without imminent debt service pressure, a durable financial advantage.
Lean Operating BaseA very small employee base implies a lean cost structure that can extend runway versus peers, lowering near‑term cash burn requirements. This operational compactness supports focused R&D activity while management seeks financing or partnerships to advance validation and clinical steps.
Bears Say
Pre‑revenue StatusNo revenue means commercial product market fit and sales execution remain unproven, creating dependence on external financing. Over the medium term this elevates dilution and execution risk because progress toward regulatory approval, reimbursement and payer adoption must be funded before sustainable revenues emerge.
Eroded Equity And Shrinking Asset BaseNegative equity and materially reduced assets signal an eroding capital base that weakens financial resilience. This impairment restricts strategic flexibility, undermines credibility with partners and investors, and increases probability of dilutive funding or restructuring if operational losses continue.
Persistent Cash BurnSustained negative operating and free cash flows require recurrent external financing to support R&D and validation. Over 2–6 months this structural cash burn raises funding risk, heightens dilution potential, and can delay or constrain critical clinical and commercial milestones needed to reach revenue generation.
Cizzle Biotechnology Holdings PLC News
E7F0 FAQ
What was Cizzle Biotechnology Holdings PLC’s price range in the past 12 months?
Cizzle Biotechnology Holdings PLC lowest stock price was €0.01 and its highest was €0.04 in the past 12 months.
What is Cizzle Biotechnology Holdings PLC’s market cap?
Cizzle Biotechnology Holdings PLC’s market cap is €9.19M.
When is Cizzle Biotechnology Holdings PLC’s upcoming earnings report date?
Cizzle Biotechnology Holdings PLC’s upcoming earnings report date is Sep 24, 2026 which is in 49 days.
How were Cizzle Biotechnology Holdings PLC’s earnings last quarter?
Cizzle Biotechnology Holdings PLC released its earnings results on Apr 30, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is Cizzle Biotechnology Holdings PLC overvalued?
According to Wall Street analysts Cizzle Biotechnology Holdings PLC’s price is currently Overvalued.
Does Cizzle Biotechnology Holdings PLC pay dividends?
Cizzle Biotechnology Holdings PLC does not currently pay dividends.
What is Cizzle Biotechnology Holdings PLC’s EPS estimate?
Cizzle Biotechnology Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cizzle Biotechnology Holdings PLC have?
Cizzle Biotechnology Holdings PLC has 424,963,200 shares outstanding.
What happened to Cizzle Biotechnology Holdings PLC’s price movement after its last earnings report?
Cizzle Biotechnology Holdings PLC reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cizzle Biotechnology Holdings PLC?
Currently, no hedge funds are holding shares in DE:E7F0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzle Biotechnology Limited, officially changed its corporate identity to Cizzle Biotechnology Holdings Plc in May 2021. Its main operational base is situated in London, United Kingdom.